| Title | Antiplatelet Drugs: Clinical Pharmacology and Pharmacokinetics | |
| Author | Charalambos T. Plessas and Stavros T. Plessas | |
| Citation | Plessas, C.T., Plessas, S.T.: Antiplatelet Drugs: Clinical Pharmacology and Pharmacokinetics, Epitheorese Klin. Farmakol. Farmakokinet. 1 (1): 5-22 (1987) | |
| Publication Date | 1987-07 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)pharmakonpress[at]pharmakonpress[.]gr | |
| Keywords | Platelets, hemostasis, thrombosis, drugs, pharmacokinetics, clinical pharmacology | |
| Other Terms | review article, aspirin, sulphinpyrazone, dipyridamole, ticlopidine, calcium dobesilate | |
| Summary | Platelets play a fundamental role in the mechanisms of the hemostasis and thrombosis. These processes result in the formation of the hemostatic plug and of an intravascular thrombus, respectively, and implicate the eicosanoids, autacoids with important physiological and pharmacological activities. Some substances, drugs or autacoids, inhibit platelet function, especially platelet adhesion to foreign surfaces, and/or platelet release reaction and platelet aggregation. The aim of this review is to present recent information about the genesis, metabolism and actions of eicosanoids, the mechanism of platelet aggregation and the phases of thrombus formation, and to describe the clinical pharmacology and pharmacokinetics (antithrombotic actions, pharmacokinetics and dose schedule) of the most important antiplatelet drugs: aspirin, sulphinpyrazone, dipyridamole, ticlopidine and calcium dobesilate. | |
| References | 1. Callus, A.S.: Antiplatelet agents re-examined. Their role in ischaemic and vascular heart disease. Med. Progr. 13(2): 61 (1986) 2. Goodman Gilman, A., Goodman, L.S., Rail, T.W., Murad, F. (eds): The Pharmacological Basis of Therapeutics. 7th ed., MacMilan Publ. Co., New York, 1985 3. De Courten, A.: Drug actions on platelet function in diabetics with microangiopathy. Epith. Klin. Farmakol. Farmakokin. 1: 270 (1984) 4. Ross, R.: The pathogenesis of atherosclerosis – an update. N. Engl. J. Med. 314: 488 (1986) 5. Moncada, S. (ed.): Prostacyclin, thromboxane and leukotrienes. Br. Med. Bull. 39: 209 (1983) 6. Hammarstrom, S.: Leukotrienes. Annu. Rev. Biochem. 52: 355 (1983) 7. Simopoulos, A.P., Kifer, R.R., Martin, R.E.’ (eds): Health effects of polyunsaturated fatty acids in seafoods. Academic Press, New York, 1986 8. Mehta, J., Lopez, L.M., Wargovich, T.: Eicosapentaenoic acid: its relevance in atherosclerosis and coronary artery disease. Circulation 59: 155 (1987) 9. Simopoulos, A.P.: Omega-3 fatty acids from fish and fish oils: Nutritional and health effects. Rev. Clin. Pharmacol. Pharmacokin. 1: 23 (1987) 10. Lewis, R.A., Austen, K.F.: The biologically active leukotrienes: Biosynthesis, metabolism, receptors, functions, and pharmacology. J. Clin. Invest. 73: 889 (1984) 11. Piper, P.: Formation and actions of leukotrienes. Physiol. Rev. 64: 744 (1984) 12. Piper, P.: Pharmacology of leukotrienes. Br. Med. Bull. 39: 255 (1983) 13. Arese, P., Bussolino, F., Biffignandi, P., De Courten, A.: Platelet-activating factor. The role of a new mediator in pathological conditions. Rev. Clin. Pharmacol. Pharmacokin. 1: 33 (1987) 14. Lentner, C. (ed.): Physical Chemistry, Composition of Blood, Hematology, Somatometric Data. Ciba-Geigy, Basel, 1984 15. Holmsen, H., Karpatkin, S.: Metabolism of platelets. In: Hematology (Williams et al. eds), 3rd ed., p. 1157, McGraw-Hill, New York, 1983 16. Vermylen, J„ Badenhorst, P.N., Deckmyn, H„ Arnout, J.: Normal mechanisms of platelet function. Clin. Haemal. 12: 107 (1983) 17. de Gaetano, G„ Cerletti, C., Dejana, E., Vermylen, J.: Current issues in thrombosis prevention with antiplatelet drugs. Drugs 31: 517 (1986) 18. George, J.N., Nurden, A.T., Phillips, D.R.: Molecular defects in interactions of platelets with vessel wall. N. Engl. J. Med. 311: 1084 (1984) 19. Packham, M.A., Mustard, J.F.: Platelet adhesion. In: Progress in hemostasis and thrombosis (Spaet ed.). Vol. 5, p. 211, Grune and Stratton, New York, 1984 20. Zucker, M.B., Nachmias, V.T.: Platelet activation. Arteriosclerosis 5: 2 (1985) 21. Fuster, V., Adams, P.C., Badimon, J.J., Chesebro, J.H.: ‘ Platelet-inhubitor drugs’ role in coronary artery disease. Progr. Cardiovasc. Dis. 29: 325 (1987) 22. Cerletti, C., Carriero, M.R., de Gaetano, G.: Platelet aggregation response to single or paired aggregating stimuli after low-dose aspirin. N. Engl. J. Med. 314: 316 (1986) 23. Weiss, H.J.: Platelets. Pathophysiology and antiplatelet drug therapy. Thromb. Haemostas. 50: 610 (1983) 24. Ross, R.: Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis 1: 293 (1981) 25. Packham, M.A.: Platelet function inhibitors. Thromb. Haemostas. 50: 610 (1983) 26. Gerrad, J.M., Peterson, D.A., White, J.G.: Calcium mobilization. In: Platelet in biology and pathology (Gordon, J.L. ed.), p. 407, Elsevier, Amsterdam, 1981 27. Kinlough-Rathbone, R.L., Mustard, J.F., Perry. D.W., Dejana, E.i Cazenave, J.-P., Packham, M.A., Harfenist, E.J.: Factors influencing the deaggregation of human and rabbit platelets. Thromb. Haemostas. 49: 162 (1983) 28. Frojmovic, M.M., Milton, J.G.: Human platelet size, shape and related functions in health and disease. Physiol. Rev. 62: 185 (1982) 29. Salzman, E.W., Merrill, E.W.: Interaction of blood with artificial surfaces. In: Hemostasis and Thrombosis: basic principles and clinical practice (Colman, R.W., Hirsh, J., Marder, V.J., Salzman, E.W.), p. 931, J.B. Lippincott Co., Philadelphia, Toronto, 1982 30. Groves, H.M., Kinlough-Rathbone, R.L., Richardson, M., Jogernsenn, L., Moore, S., Mustard, J.F.: Thrombin generation and fibrin formation following injury to rabbit neointima: studies of vessel wall reactivity and platelet survival. Lab. Invest. 46: 605 (1982) 31. Marks, G.S.: Determinants of the pharmacokinetics of antithrombotic drugs. Thromb. Res.. Suppl. IV: 17 (1983) 32. Thiessen, J.J.: Aspirin: Plasma concentration and effects. Thromb. Res., Suppl. IV: 105 (1983) 33. FitzGerald, G.A., Oates, J.A., Hawiger, J., Maas, R.L., Roberts II, L.J. et al.: Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest. 71: 676 (1983) 34. Weksler, B.B., Tackgoldman, Κ., Subramanian, V.A., Gay, W.A.: Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation 71: 332 (1985) 35. Weksler, B.8., et al.: Differential inhibition by aspirin of vascular and prostaglandin synthesis in atherosclerotic patients. N. Engl. J. Med. 308: 800 (1983) 36. DiMinno, G., Silver, M.J., Murphy, S.: Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 61: 1081 (1983) 37. Cerletti, C., Carriero, M.R., de Gaetano, G.: Platelet aggregation response to single or paired aggregating stimuli after low-dose aspirin. N. Engl. J. Med. 314: 316 (1986) 38. Del Maschio, A., Liyio, M., Cerletti, C., de Gaetano, G.: Inhibition of human platelet cyclo-oxygenase activity by sulphinpyrazone and three of its metabolites. Eur. J. Pharmacol. 101: 209 (1984) 39. Pedersen, A.Κ., FitzGerald, G.A.: Cyclooxygenase inhibition, platelet function and metabolic formation during chronic sulphinpyrazone dosing. Clin. Pharmacol. Ther. 37: 36 Π 985) 40. Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N. Engl. J. Med. 302: 250 (1980) 41. Hampton, J.R.: The secondary prevention of heart attacks. J. Ir. Coll. Physic. Surg. 11: 143 (1982) 42. Harker, L.A.: Mechanism of action of dipyridamole. Thromb. Res. Suppl. IV: 39 (1983) 43. Gresele, P., Zoja, G. (Deckmyn, H., Arnout, J., Vermylen, J. et al.: Dipyridamole inhibits platelet aggregation in whole blood. Thromb. Haemostas. 50: 852 (1983) 44. Di Minno, G.r Villa, S., Berteli, V., de Gaetano, G.: Dipyridamole as an anti-thrombotic agent: an intricate mechanism of action. In: Diet and drugs in atherosclerosis (Noseda et al. eds), p. 121, Raven press, New York, 1980 45. Kinlough-Rathbone, R.L., Packham, M.A., Mustard, J.F.: Vessel injury, platelet adherence, and platelet survival. Arteriosclerosis 3: 529 (1983) 46. Mahoney, G., Wolfram, K.M., Cocchetto, B.S., Bjornsson, T.D.: Dipyridamole kinetics. Clin. Pharmacol. Ther. 31: 330 (1982) 47. Mahony, C. et al.: Plasma dipyridamole concentrations after two different dosage regimens in patients. J. Clin. Pharmacol. 23: 123 (1983) 48. Buckler, P., Douglas, A.S.: Antithrombotic treatment. Br. Med. J. (din. Res.) 287: 196 (1983) 49. de Gaetano, G., Bertele, V.: Antiplatelet drugs and thrombosis prevention: tiplopidine in perspective. Agents Actions 14: 109 (1984) 50. Panak, E., Maffrand, J.P., Picard-Fraire, C., Valle, E. et al.: Ticiopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis 13 (Suppl. 1): 1 (1983) 51. Bruno, J.J.: The mechanisms of action of ticiopidine. Thrombos. Res. Suppl. IV: 59 (1983) 52. Di Minno, G., Cerbone, A.M., Mattioli, P.L., Lovine, C., Mancini, M.: Functionally thrombostenic state in normal platelets following the administration of ticiopidine. J. Clin. Invest. 75.: 328 (1985) 53. Symposium (Various authors): Symposium on pharmacokinetic and pharmacodynamic approach to antithrombotic therapy (M.R. Buchanam, J. Rosenfeld•, eds). Thromb. Res. Suppl. 4: 1 (1983) 54. Fox, K.M., Jonathan, A., Selwyn, A.P.: Efifects of platelet inhibition on myocardial ischaemia. Lancet 2: 727 (1982) 55. Plessas, C.T., Varonos, D., Plessas, S.T., Cokkinos, D., Voridis, E.: Calcium dobesilate-35S blood studies in the rabbit. Acta Therap. 5: 341 (1979) 56. Michal, M., Crotti, C., Giessinger, N.: Effect of Doxium on platelet function in vivo and in vitro. XVIIIth Congress of Eur. Soc. Surg. Res. Book of abstracts, p. 89, Athens, 1983 57. Michal, M., Giessinger, N.: Effect of calcium dobesilate and its interaction with aspirin on thrombus formation in vivo. Thromb. Res. 40: 215 (1985) 58. Gloviczki, P., Fowl, R.J., Hollier, J.H., Dewanjee, M.K., Plate, G., Kaye, M.P.: Prevention of platelet deposition by ibuprofen-and calcium dobesilate in expanded polytetrafluoroethrylene vascular grafts. Am. J. Surgery 150: 589 (1985) 59. Heidrich, H., Gerke, £., Nekarda, H.: Inhibition of platelet aggregation under calcium dobesilate. Drug. Res. 33(1), 4: 580 (1983) 60. Pfliegler, G., Boda, Z„ Udvardy, M., Beck, P., Misz, M., Vincze, P.: Effect of calcium dobesilate treatment on haemostasis and serum lipids in diabetic patients. Acta Ther. 12: 71 (1986) 61. Rauscha, F., Sinzinger, H., Vinazzer, H.: Calcium dobesilate and platelet function in patients with peripheral vascular disease. XlVth World Congr. Int. Un. Ang., Book of abstracts, Munich, 1986 62. Barras, J.P., Graf, C.: Hyperviscosity in diabetic retinopathy treated with Doxium (calcium dobesilate). Vasa 9: 161 (1980) 63. de Courten, A.: Action des medicaments sur la fonction plaquettaire chez les diabitiques avec microangiopathie. Rev. Clin. Pharmacol. Pharmacokin. 1: 270 (1984) 64. Plessas, S.T., Plessas, C.T., Benakis, A.: Correlations entre modifications rheologiques au niveau sanguin et liaison avec les constituents du sang du Doxium. XII World Congress of Angiology, Book of abstracts, p. 284, Athens, 1980 65. Benakis, A., Glasson, B., Bouvier, C.A., Ritschard, J., Krahenbhul, B., Jung, A., Hachen, H.J.: Metabolism and pharmacokinetics of calcium dobesilate in man. Therapie 29: 211 (1974) 66. Plessas, Ch.T., Plessas, S.T., Benakis, A.: Pharmacokinetics of calcium dobesilate in man after rapid intravenous administration. XII World Congress of Angiology, Book of abstracts, p. 365, Athens, 1980 67. Plessas, C.T., Varonos, D., Plessas, S.T., Cokkinos, D„ Voridis, E.: The role of dextran on the blood level of 36S-calcium dobesilate in humans. Eur. J. Durg. Metabol. Pharmacokin. 2: 123 (1976) 68. Plessas, C.T., Karayannakos, P., Plessas, S.T., Costakis, A., Donta, l„ Skalkeas, G.: Pharmacokinetics of calcium dobesilate in beagle dogs after a single administration. Eur. J. Durg. Metabol. Pharmacokin. 4: 303 (1986) 69. Szlavy, L., Repa, I., de Courten, A.: Influence of a lympha- gogue, CLS2210, on regional cardiac lymphatics and the electrocardiogram after coronary artery occlusion in the dog. Lymphology 19: 15 (1986) 70. Plessas, Ch.T., Karayannakos, P., Plessas, S.T., Costakis, A., Donta, I., Skalkeas, G.: Pharmacokinetics of calcium dobesilate in beagle dogs after repeated administration. Eur. J. Durg. Metab. Pharmacok. 11: 309 (1986) 71. Szlavy, L, Repa, I., deCourten, A., Hollenberg, N.K., Adams, D.: The effect of CLS2210 on cardiac lymphatics and infarct size. Int. Congress of Angiology, Athens, Greece, 1985 |
|
| Relative Papers | Platelet-Activating Factor – PAF: the role of a new mediator in pathological conditions Paolo Arese, Federico Bussolino, Paolo M. Biffignandi, A. de Courten |
|
Online ISSN 1011-6583
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 1987 – ANNUAL SUBSCRIPTION 1987 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)pharmakonpress[at]pharmakonpress[.]gr | |